ライフサイエンスコーパス: survival rate

1 p 2B exhibited the lowest performance (56.7% survival rate).

2 ip breeding often but have the highest adult survival rate.

3 rsely associated with higher overall patient survival rate.

4 els of CA9 promoter methylation had a higher survival rate.

5 n of EOC cells are the major reasons for low survival rate.

6 ated with tumor size, disease recurrence and survival rate.

7 ted with decreased pancreatic cancer patient survival rate.

8 ats per minute was equivalent to the control survival rate.

9 ative acute respiratory failure had the best survival rate.

10 ghly lethal with less than 5% overall 5-year survival rate.

11 l ischemia/reperfusion injury, allowing 100% survival rate.

12 especially problematic, with a 50 % average survival rate.

13 cancer-related deaths worldwide with a poor survival rate.

14 y, although they do not significantly affect survival rates.

15 standard oxygen did not reduce intubation or survival rates.

16 Endpoints were short- and long-term survival rates.

17 of surgical resection and increasing 5-year survival rates.

18 cantly lower than 1-year posttransplantation survival rates.

19 with AML by 20-25% while maintaining overall survival rates.

20 act of the empirical antibiotic treatment on survival rates.

21 te more tumor cells and increase the overall survival rates.

22 cancer deaths worldwide with stagnant 5-year survival rates.

23 cal intervention is associated with improved survival rates.

24 ehavior, circulating disease biomarkers, and survival rates.

25 esions (ITBL) with subsequent impaired graft survival rates.

26 ectively) with decreased treatment efficacy (survival rates 0.38 [95% CI 0.25-0.51] and 0.41 [0.28-0.

27 carcinoma (HCC) has the second lowest 5-year survival rate ( 16%) of all tumor types partly owing to

28 dependent with hatchlings having the lowest survival rates (16%) but increasing to nearly 90% at adu

29 atients (48%) had major response with 3-year survival rate (3-YSR) of 57% compared with 44 patients w

30 6 months vs 18.4 months; P = .40), or 3-year survival rate (31% vs 25%; P = .50).

31 eficient (Opn (-/-)) mice exhibited a higher survival rate (70%) than wild type (WT) control mice (30

32 d at high-volume centers had better pancreas survival rates across all categories of the Pancreas Don

33 Although differences in patient survival rates across data sources were small (</=1 perc

34 has a poor prognosis with wide variation in survival rates across the world.

35 model and an adjusted difference in absolute survival rates (adjusted rate difference) of 3.1% (95% C

36 e primary end point was the progression-free survival rate after 6 months (PFS-6).

37 inflammatory cytokine production and a lower survival rate after cecal ligation and puncture.

38 t provides efficient hemodynamic support and survival rate after the implantation is 50%.

39 The 5-year disease-specific survival rate after tumor resection was 65%.

40 Because survival rates after a diagnosis of childhood cancer hav

41 Overall graft survival rates after DMEK ranged from 92% to 100% at las

42 bility complex (MHC) matching improves graft survival rates after organ transplantation.

43 koc1 Arabidopsis seedlings had reduced survival rates after transfer from the dark to the light

44 measured by neutralizing antibody titers and survival rates after virus challenge.

45 ther large, long-lived reptiles: while adult survival rates always have a large impact on population

46 though no statistical differences in overall survival rates among cohorts were observed, the data sug

47 With these treatment regimens, survival rates among HIV-infected adults who are retaine

48 ted statistically significant differences in survival rates among the groups ( P = 0.048).

49 in or hemopexin but not albumin improved the survival rate and attenuated SRBC-induced inflammation.

50 with CS, Ani/Neo combination increased 24 h survival rate and decreased the levels of H2O2, MPO, NO,

51 rowing host axons, while NCSCs showed better survival rate and distribution.

52 is closely correlated with a low cumulative survival rate and metastatic progression in HCC patients

53 ive studies which reported on posttransplant survival rates and 10 comparative studies which reported

54 To compare survival rates and causes of death among patients with i

55 present study was to investigate the 5-year survival rates and causes of late death in this group of

56 dy of cancer genomes is intended to increase survival rates and decrease treatment-related toxicity.

57 hich correlated with significantly decreased survival rates and heightened levels of proinflammatory

58 Specifically, low infant survival rates and high rye yields (an important food so

59 ated Axl-KO mice had significantly increased survival rates and improved renal function compared with

60 We observed higher hair cell survival rates and lower auditory brainstem response thr

61 year follow-up, there were no differences of survival rates and occurrences of newly diagnosed crypto

62 -analysis of cohort studies to assess pooled survival rates and prognostic factors for survival in pa

63 poor pretreatment laryngeal function, better survival rates and quality of life may be achieved with

64 neficial effects were evidenced by a greater survival rate, and in both murine models, they were evid

65 5-year period; lifetime HIV infection risk, survival rate, and program cost and cost-effectiveness;

66 rmination rates, weak seedlings with reduced survival rates, and eventually lower yields.

67 abidopsis lines increased germination rates, survival rates, and increased primary root length compar

68 Rates of adherence to quality indicators, survival rates, and medical payments (excluding bonuses

69 vival to discharge measured as risk standard survival rates, and the secondary outcome was favorable

70 Our aims were to evaluate incidence, survival rates, and volume of LP centers with Bayesian,

71 5-year event-free, disease-free, and overall survival rates are 85%, 96%, and 88%, respectively.

72 Five- and 10-year survival rates are approximately 85% to 95% and 75%, res

73 ic disease and for these children the 5-year survival rates are dismal.

74 Survival rates are further positively associated with fo

75 1-year graft survival rates are greater than 95% in many centres but

76 ong high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic-val

77 netically heterogeneous disorder but data on survival rates are still conflicting and have not so far

78 by age and molecular subtype to investigate survival rate associated with RT.

79 in the imatinib group, the estimated overall survival rate at 10 years was 83.3%.

80 The overall survival rate at 3 years was 58% in the nivolumab-plus-i

81 denocarcinoma (PDAC) has single-digit 5-year survival rates at <7%.

82 ith (val-)ganciclovir (n = 63), the CMV-free survival rates at 1 year and 3 years posttransplant (100

83 Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/3

84 sex, age, and socioeconomic status (SES) on survival rates based on the Surveillance, Epidemiology,

85 The absolute difference in this survival rate between these patients and those who recei

86 d to calculate 5-year overall and event-free survival rates by cancer stage, and the Cox proportional

87 We have achieved a perioperative survival rate close to 100%.

88 higher 1-year heart failure readmission-free survival rate compared with the non-normalized group (n=

89 nerally achieve comparable patient and graft survival rates compared to their HIV-uninfected counterp

90 transplant rejection, retransplantation, and survival rates compared with other groups.

91 late effects will likely increase as cancer survival rates continue to improve.

92 ffect of EBOTAb given post-exposurally, with survival rates decreasing with increasing time after cha

93 imilar results in terms of patient and graft survival rates despite significant differences in donors

94 In conclusion, drug survival rates differed among biologic therapies and dec

95 The disease-free survival rate difference was 0.3% (favoring TLH; 95% CI,

96 ging patterns in adult and juvenile apparent survival rates, driven by spatial and temporal variation

97 The overall 1-, 2-, and 5-year postdischarge survival rates following cardiopulmonary resuscitation w

98 primary analysis was the 5-year Kaplan-Meier survival rate for each criterion.

99 will lead to significant improvements in the survival rate for ovarian cancer.

100 oarray analysis showed that the disease-free survival rate for patients with high-expression of AR wa

101 The primary outcome was one-year event-free survival rate for the combined end point of death and ho

102 oid cancer have a good prognosis; the 5-year survival rate for thyroid cancer overall is 98.1%.

103 Five-year actuarial survival rates for all exposure groups, age-adjusted and

104 Recipient and graft survival rates for hearts and lungs were 75% (n = 4) and

105 Survival rates for kidney and liver recipients were 100%

106 Graft survival rates for kidneys and livers were 15 of 16 (94%

107 ical cancer and unlike most other neoplasms, survival rates for OC have not significantly improved in

108 iad of ways resulting in dramatically higher survival rates for our sickest patients.

109 study, RR, 1.17; 95% CI, 1.03-1.32) post-LT survival rates for patients who received LRT.

110 The 5-year event-free survival rates for patients with stages 0 to III breast

111 Overall survival rates for the entire cohort were 65% at 3 years

112 Long-term Kaplan-Meier (K-M) survival rates for those with and without MLNR were comp

113 The 24-month disease-free survival rate from time of CR was 90.9% in all 105 patie

114 care and community settings pose a threat to survival rates from serious infections, including neonat

115 s, which are associated with a reduced graft survival rate, has become widely adopted in elderly reci

116 Currently, 5-year survival rates have plateaued at ~70% for patients with

117 likely to offer additional benefits, because survival rates have reached a plateau.

118 .05; 95% CI 0.95-1.17), and progression free survival rates (HR 1.01; 95% CI, 0.92-1.11).

119 tinum-containing nanodrug, as well as animal survival rate in a HT-29 xenograft mouse model.

120 hibiting the tumor growth and prolonging the survival rate in an aggressive murine breast cancer mode

121 ing combination therapy show that the 3-year survival rate in PAH may be as high as 84% compared with

122 The overall drug survival rate in the first year after switching was 77%

123 cued the locomotive defects and enhanced the survival rate in transgenic flies expressing FUS.

124 hPR3Tg displayed decreased survival rates in acute sepsis, associated with increase

125 We found that CD47mAb treatment improved survival rates in both models.

126 1/Csn5 overexpression is correlated with low survival rates in cancer patients, including nasopharyng

127 vention of these occurrences and thus better survival rates in childhood cancer.

128 maternal age at reproduction, brood size and survival rates in combination with DNA methylation sensi

129 tly delaying tumor progression and improving survival rates in mice models.

130 our regression and markedly improves overall survival rates in mouse tumour models.

131 Discouraging survival rates in patients treated early after allogenei

132 Purpose Significantly improved survival rates in patients with Ewing sarcoma have raise

133 Importantly, the 4 and 5-year survival rates in the experimental group (83.2% and 76.3

134 Although 5-year survival rates in the first-line setting range from 60%

135 A expression correlates with reduced patient survival rates in the MMRF CoMMpass data set.

136 The 5-year graft survival rates in the responding patients and the nonres

137 raginase) resulted in significantly improved survival rates in xenografted mice.

138 The 21-day survival rates increased between the two 8-year periods

139 The patient's survival rate is uncertain due to the limitations of can

140 However, despite improvements in survival rates, it is now apparent that the targeting of

141 Samples were analyzed using microbiological (survival rates), morphological (electron microscopy), bi

142 Fourteen-day survival rate, neurocognitive function, and endothelial

143 The overall survival and progression-free survival rates observed in this trial are encouraging co

144 evastating prognosis, with an overall 5-year survival rate of 8%, restricted treatment options and c

145 eadly cancer in the US, with a meager 5-year survival rate of <20%.

146 ve in all nine field experiments with a mean survival rate of 0.57, ranging from 0.41 to 0.75.

147 ntly from 2007 through 2012, with an overall survival rate of 30.4%.

148 S) are rare mesenchymal tumors with a 5-year survival rate of 50%, highlighting the need for further

149 An estimated 5-year survival rate of 55% post-engraftment for an 80-year-old

150 rate of 73% (95% CI, 65%-79%) and a 24-month survival rate of 60% (95% CI, 51%-68%).

151 (95% CI, 24 to not reached) with a 12-month survival rate of 73% (95% CI, 65%-79%) and a 24-month su

152 with the highest levels of parasitemia had a survival rate of 83%.

153 We assumed a 3-year invasive-disease-free survival rate of 91.8% with pertuzumab and 89.2% with pl

154 ropout patient and 1 failure, resulting in a survival rate of 94.7% after 1 y, in comparison to 100%

155 hese patients had a 20-year disease-specific survival rate of 97%, whereas for untreated patients the

156 vival rate of approximately 50% and a 2-year survival rate of approximately 16%.

157 at 1 month followed by a 6-month and 1-year survival rate of approximately 50% and a 2-year survival

158 r approximately one half of the disparity in survival rate of black vs white patients with CRC, 18-64

159 h butterflies to infection, they reduced the survival rate of caterpillars to adulthood.

160 The simulated 10-y survival rate of crowns fabricated from YZ was only slig

161 and MAP3K14(aly/aly) mice did not affect the survival rate of either group after folic acid injection

162 The overall 7-y survival rate of ETT restored with fiber post and either

163 from 2000 to 2012, it was concluded that the survival rate of HLA poorly matched living donor transpl

164 ECG association was also proportional to the survival rate of mice across genotypes.

165 te that delivery of mBPIN-GVNPs increase the survival rate of mice challenged with lethal concentrati

166 his approach leads to a significantly higher survival rate of nanoinjected cells and that injection w

167 c melanoma have an estimated 5-year relative survival rate of only 17%.

168 a cancer with poor prognosis, and the 5-year survival rate of patients with metastatic RCC is 5-10%.

169 excess free volume contribute to a decreased survival rate of point defects in cascades occurring adj

170 The low in vivo survival rate of scaffold-seeded cells is still a challe

171 ntiation, metastasis to lymph nodes, and the survival rate of the patients with GC.

172 mpared to typical liver cancers, with 5-year survival rates of 57% to 100% versus 12% to 68%, respect

173 ree risk strata with 6-year kidney allograft survival rates of 6.0% (high-risk group, n=40), 44.9% (i

174 However, variable survival rates of 60-80% and debilitating chemotherapy s

175 (P = .04), with 12- and 24-month event-free survival rates of 78% and 70%, respectively, in the low-

176 P = .00013), resulting in 5-year event-free survival rates of 83.9 +/- 0.9% for dexamethasone and 80

177 ge III, T4a-bN0-3 resulted in 3-year overall survival rates of 91%, 87%, 81%, and 70%, respectively.

178 8%, respectively, with concomitant recipient survival rates of 97%, 93%, 85%, and 79%, respectively.

179 low (n = 8; 0.5%/year), with 5- and 10-year survival rates of 99% and 97%, respectively, which is no

180 By correlating the survival rates of cells with their respective water stat

181 With 1 year renal graft survival rates of greater than 90% the best that can be

182 Additionally, survival rates of hosts (larval gray treefrogs; Hyla ver

183 TmCactin RNAi significantly decreased the survival rates of larvae after challenge with Escherichi

184 ng and pancreatic cancers, which have 5 year survival rates of less than 10%, into an untreatable can

185 de (LaCl3) or auranofin (AUR), also increase survival rates of mice undergoing cecal-ligation-and-pun

186 To compare long-term survival rates of patients with first, primary, clinical

187 Survival rates of Ret wild-type, null heterozygote and n

188 slow clearance rates associate with enhanced survival rates of ring-stage parasites briefly exposed i

189 survival was not sustained since the 1-year survival rates of small cell lung cancer, non-small cell

190 Survival rates of the species are lowest in areas with i

191 Posttransplant cancer risk and survival rates of these patients are unknown.

192 ismatches on graft survival was analyzed and survival rates of transplants from poorly matched living

193 Secondary outcomes were progression-free survival; rates of grade 3 or 4 adverse events; and the

194 The survival rate on hospital discharge was remarkably high,

195 idney and liver transplantation, with 1-year survival rates over 80%; however, improving longer-term

196 The prognosis is poor and the five-year survival rate ranges from 20% (OSCC in the floor of the

197 dromic CIDs had a significantly lower 5-year survival rate rather than those with nonsyndromic CIDs.

198 There was no difference in graft survival rate regarding the original indication of PK or

199 Survival rates remain low after hemorrhage-induced traum

200 distinguish sites with higher cardiac arrest survival rates remain unknown.

201 ained very good, with the 5-year and 10-year survival rates reported to be 93.8% and 84.9%, respectiv

202 en to reflect experimentally observed thymic survival rates result in near-optimal production of T ce

203 remained 7 months, and the 12-month relative survival rates (RSRs) remained relatively stable at 32.9

204 leic acid (DNA) contents, cellular sizes and survival rates similar to those of free-living bacteria.

205 romise, with 3- and 5-year patient and graft survival rates similar to those of their HIV-uninfected

206 th a high metastatic rate and a lower 5-year survival rate than for other breast cancer phenotypes, m

207 at a late stage, resulting in a lower cancer survival rate than in the European Region and the Region

208 K1-deficient mice had a significantly higher survival rate than wild-type control mice in response to

209 responses to radiotherapy and higher overall survival rates than do patients with HPV-negative HNSCC,

210 60 years or older is associated with higher survival rates than remaining on dialysis, whereas livin

211 y data often yielded slightly higher patient survival rates than sources including external death dat

212 amic materials (FM and LR) resulted in lower survival rates than the more recently developed higher-s

213 e dose of RT for large IHCCs, with long-term survival rates that compare favorably with resection.

214 to be 93.1%; 5-year and 10-year disease-free survival rates to be 75.7% and 71.0%, respectively; and

215 respectively; and 5-year and 10-year overall survival rates to be 78.9% and 73.5%, respectively.

216 ority black neighborhoods had lower adjusted survival rates to hospital discharge (25%-50% black: odd

217 tly higher hydraulic conductivity levels and survival rates under both normal and drought conditions.

218 Patient survival rates varied minimally with augmented data sour

219 5-year survival rates vary from 4-17% depending on stage and re

220 Five-year ESRD-free survival rate was 21% for diffuse mesangial sclerosis.

221 The resection rate was 75%, and the 5-year survival rate was 24%.

222 Their 1-year survival rate was 42%; most of the survivors were transp

223 24-month overall survival rate was 55% in the 2-week group, 55% in the 3-

224 At 5 years, the overall survival rate was 57% in the intensive arm and 47% in th

225 -up of 370 days, the 1-year progression-free survival rate was 58.2% (95% CI, 33.1%-76.7%) and the ov

226 as 16.3 (11.47-22.57) months, and the 1-year survival rate was 62%.

227 The estimated 12-month survival rate was 66% (95% CI, 55.6-74.8).

228 The survival rate was 73% (n = 242) at the end of the study.

229 hereas no patients died from PBC, the 5-year survival rate was 75%, as compared to 90% in a control,

230 The 10-year survival rate was 76%.

231 58.2% (95% CI, 33.1%-76.7%) and the overall survival rate was 78.7% (95% CI, 52.4%-91.5%).

232 The 5-y BCR-free survival rate was 80.5% and 69.9% in the ePLND+SNB and e

233 The 5-year overall survival rate was 80.7%.

234 dian center-level 1-year posttransplantation survival rate was 84.1%, and the median center-level ITT

235 The 2-year overall survival rate was 84.9% (95% confidence interval [CI], 8

236 se), the estimated 18 month progression-free survival rate was 86% (95% CI 66-94), and the estimated

237 The 3-year overall survival rate was 86% in the combination-therapy group a

238 he first 90 days after treatment, the 5-year survival rate was 87% and was particularly beneficial in

239 rs; range, 20-44 years) the 5-year actuarial survival rate was 87.5% (95% CI, 86.5%-88.4%) for women

240 The probable 10-year survival rate was 89% (95% CI, 84%-94%).

241 e was 96.1% (95.8-96.4), and 20-year implant survival rate was 89.7% (87.5-91.5).

242 The 5-year estimated overall survival rate was 89.9% for letrozole versus 89.2% for a

243 The 2-year invasive disease-free survival rate was 93.9% (95% CI 92.4-95.2) in the nerati

244 e of 97%, whereas for untreated patients the survival rate was 94%.

245 The 5-year enucleation-free survival rate was 94.8% in the endoresection group, 94.3

246 The 5-year disease-free survival rate was 95% (95% confidence interval [CI], 93

247 For total hip replacement, 10-year implant survival rate was 95.6% (95% CI 95.3-95.9) and 20-year r

248 For total knee replacement, 10-year implant survival rate was 96.1% (95.8-96.4), and 20-year implant

249 The 1-, 3-, and 5-year patient survival rate was 96.4% during the mean follow-up period

250 The 1-, 3-, and 5-year graft survival rate was 96.4%, 94.2%, and 92.0%, respectively,

251 The 5-year actuarial survival rate was 96.7% (95% CI, 94.1%-99.3%) for women

252 I 66-94), and the estimated 18 month overall survival rate was 97% (95% CI 79-100).

253 At a median follow-up of 2 years, the survival rate was 97%; one patient died during the study

254 The overall survival rate was estimated using Kaplan-Meier method.

255 ne expression, and a significantly decreased survival rate was observed, together with a molting bloc

256 The highest 84-mo survival rate was recorded in group 1A (90%), whereas te

257 The survival rate was similar in the two groups, but the rat

258 r adjusting for these factors, difference in survival rates was no longer significant (hazard ratio 0

259 pectively, and the estimated 10-year overall survival rates were 19.4% and 21.5%, respectively.

260 OS times were 8.9 and 9.8 months, and 1-year survival rates were 25% and 37% (hazard ratio, 0.78; 95%

261 Twelve-month progression-free survival rates were 35% (95% CI, 31%-39%) in the total p

262 Five-year disease-free survival rates were 39% in the FU plus LV arm and 37% in

263 status the median survival times and 5-year survival rates were 41.6, 27.5, and 23.4 months; and 37.

264 Ten-year ESRD-free survival rates were 43%, 94%, and 72% in children with I

265 me to treatment failure and progression-free survival rates were 44% (95% CI, 39% to 49%) and 48% (95

266 low-up duration of 6.5 years, 5-year overall survival rates were 44% in the FU plus LV arm and 44% in

267 Survival rates were 50% and 89% in the control and hyper

268 The 2-year and 5-year overall survival rates were 52% (95% CI, 36%-66%) and 30% (95% C

269 The 5-year Kaplan-Meier survival rates were 57%, 51%, and 30% for criteria 1, 2,

270 months; 1-year progression-free and overall survival rates were 60% and 85%, respectively (median fo

271 The cumulative 5- and 10-year overall survival rates were 63.1% and 48.7%, respectively.

272 98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) and 52% (95%

273 section, ITT 5-year overall and disease-free survival rates were 69% and 60%, respectively.

274 The respective 5-year thalassemia-free survival rates were 73% (95% CI, 51-86%) and 92% (95% CI

275 year, and actuarial 15-year overall patients survival rates were 73%, 45%, and 39%, respectively, for

276 Two-year overall survival rates were 77.6% in patients with nonprogressiv

277 2-year progression-free survival and overall survival rates were 80% and 94%, respectively, for patie

278 to ALBI grade, the cumulative 5- and 10-year survival rates were 80.0% and 67.9% for patients with gr

279 5-year progression-free survival rates were 81% (95% CI 71-87) for group A, 86%

280 l HR was 0.75 (90% CI, 0.38 to 1.45); 2-year survival rates were 88.4% and 93.0%, respectively.

281 The 1-year and 3-year survival rates were 89.0% and 76.7% in the SLK-HCC group

282 The estimated 10-year progression-free survival rates were 9.5% and 9.2% for the 400- and 800-m

283 , 3-, 5- and 7-year death-censored allograft survival rates were 98%, 91%, 86%, and 78%, respectively

284 rs, the 1-month, 3-month, 1-year, and 5-year survival rates were 99%, 95%, 86%, and 76%, respectively

285 Linkage to care, mortality and survival rates were calculated according to WHO criteria

286 Survival rates were calculated using the Kaplan-Meier me

287 Unadjusted Kaplan-Meier 3-year patient survival rates were computed using 4 nonmutually exclusi

288 Survival rates were different between molecular subgroup

289 Lesion-free survival rates were estimated using Kaplan-Meier surviva

290 tients), the 5-year and 10-year disease-free survival rates were reported to be 86.4% and 78.7%, resp

291 The overall survival and disease-free survival rates were significantly worse for patients wit

292 The 1-year patient and graft survival rates were similar between groups.

293 The patient (P = .313) and graft (P = .263) survival rates were similar in the 2 preservation groups

294 The 5-year event-free and overall survival rates were, respectively, 85% and 92.7% for CNS

295 ML, those patients with CN-AML have a poorer survival rate when GFI1 expression is high.

296 CA2 alterations showed elevated disease-free survival rates when carboplatin was added (without carbo

297 fixed dental prostheses have high long-term survival rates when inserted with conventional cements.

298 Results Two-year overall survival rates with nivolumab versus docetaxel were 23%

299 zard ratios and to compare 30-day and 1-year survival rates with the myocardial infarction/cardiogeni

300 ukemia in the United States, has the poorest survival rate, with 26% of patients surviving 5 years.